The CDC is a major player in the vaccine marketplace, buying half of all childhood vaccines in the U.S. and then selling them to contracted public health agencies through the Vaccines for Children (VFC) Program, which pushes free and low-cost vaccines on indigent children. Over the past three decades, the CDC’s vaccine purchases have increased 15-fold as the average cost of fully vaccinating a child to age 18 rose from $100 to $2192—while vaccine companies have raked in the profits. The agency’s involvement with vaccine manufacturers also extends to patents, licensing agreements and collaboration on projects to develop new vaccines. In fact, the CDC and the National Institutes of Health (NIH) profit handsomely from their ownership or co-ownership with private sector partners of vaccine-related patents. Some of the key technologies underlying the development of the HPV vaccines Gardasil and Cervarix emerged from research patented by the NIH’s National Cancer Institute (NCI), which then licensed the technology to Merck, MedImmune and GlaxoSmithKline. By 2009, HPV licensing had become NIH’s top generator of royalty revenues. Gardasil is “perhaps the leading example of a new form of unconstrained government self-dealing, in arrangements whereby [HHS] can transfer technology to pharmaceutical partners, [and] simultaneously both approve and protect their partners’ technology licenses while also taking a cut of the profits.” It seems doubtful that agencies can remain impartial in the face of these profits.
It has been 13 years since the U.S. Food and Drug Administration (FDA) supplied fast-tracked approval for Merck’s Gardasil vaccine—promoted for the prevention of cervical cancer and other conditions attributed to four types of human papillomavirus (HPV). The agency initially licensed Gardasil solely for 9- to 26-year-old girls and women, but subsequent FDA decisions now enable Merck to market Gardasil’s successor—the nine-valent Gardasil 9 vaccine—to a much broader age range—9 to 45 years—and to both males and females. As a result of Gardasil’s expanding markets not just in the U.S. but internationally, the blockbuster HPV vaccine has become Merck’s third highest-grossing product, bringing in annual global revenues of about $2.3 billion. However, Gardasil’s safety record has been nothing short of disastrous. Children’s Health Defense and Robert F. Kennedy, Jr. have just produced a video detailing the many problems with the development and safety of Gardasil. What follow are 25 key facts about Gardasil/Gardasil 9, including facts about the HPV vaccines’ clinical trials and adverse outcomes observed ever since Merck, public health officials and legislators aggressively foisted the vaccines on an unsuspecting public.
New Research: High HPV Cancer Rates Linked to High Gardasil Vaccination Rates – “Exactly the Opposite of what we Expected”
Last year (2018) we reported on the research of French oncologist Dr. Gérard Delépine, who published an analysis of the HPV vaccine Gardasil showing how increased rates of Gardasil vaccinations are actually correlated with a higher rate of cervical cancer. Now, researchers at the University of South Alabama are observing the same link of increased Gardasil vaccination rates with an increased rate of HPV related cervical cancers in Alabama. The researchers and medical doctors commented that this was a "surprising discovery" and that it was "exactly the opposite of what we expected." It is highly unlikely this will be reported in any of the corporate-sponsored "mainstream" media sources.
Robert F. Kennedy, Jr. is one of the attorneys in the Jennifer Robi vs. Merck and Kaiser Permanente fraud case currently being litigated in Los Angeles Superior Court. This must-watch video, referencing much of the science presented as evidence during the trial, details the many problems with the development and safety of Merck’s third-highest grossing product, Gardasil. Children’s Health Defense (CHD) and Robert F. Kennedy, Jr., CHD’s Chairman and Chief Legal Counsel, ask that you watch and share this video so that you, and others, may make an informed decision of whether or not to give your child, boy or girl, a Gardasil vaccine. It can also be a useful tool for pediatricians who are trying to understand how this vaccine, that is actually causing health problems with young people, could have been approved by FDA and then recommended by CDC. The video is full of jaw-dropping facts about Gardasil and the clinical trials leading up to its release upon an unsuspecting public.
Merck Sees “Unprecedented” Growth in Gardasil Vaccine – Over $3 Billion in Sales in 2018 with Expansion into China
Vaccine manufacturer Merck & Co. has reported earnings from its Gardasil HPV vaccine for 2018 at $3.15 billion, far above the previous year sales of $2.31 billion. First quart of 2019 sales of the Gardasil vaccine have soared 31% to $838 million for the first three months of 2019. Executives from the company have stated that these sales of the Gardasil vaccine are "unprecedented," and the company plans to spend over $1 billion to expand its Gardasil vaccine production. Much of this growth of the Gardasil vaccine market is due to Merck's expansion into China. While many other countries, like Japan, are pulling back on their recommendations for the Gardasil vaccines due to the sheer volume of reported Gardasil vaccine injuries, and the resulting lawsuits in those countries against Merck and its distributors, something that is not possible in the United States due to the legal immunity vaccine makers enjoy, China is running full speed ahead to introduce the Gardasil vaccine to its population.
Pharmaceutical giant Merck's political influence is now reaching beyond the CDC and federal government, and moving into state legislatures as several states have introduced bills to mandate Merck's Gardasil HPV vaccine for children. The HPV vaccine, which only applies to sexually active people, is not currently part of the CDC vaccine schedule, therefore separate legislation is needed to compel children to receive it. What is withheld from the public is the fact that Merck is fighting fraud cases in U.S. courts and multiple other lawsuits around the world concerning the Gardasil vaccine, as the vaccine continues to kill and injure, primarily teenage girls. Here are the states currently considering new legislation to mandate the deadly Gardasil vaccine against parental choice.
After the U.S. Food and Drug Administration’s (FDA) approved Merck’s HPV-9 Gardasil vaccine for use in adults age 27 to 45 in 2018, the Centers for Disease Control’s (CDC) Advisory Committee on Immunization Practices (ACIP) of the Department of Health and Human Services (HHS) is evaluating whether to expand their current HPV vaccine recommendation to include this new age group. ACIP’s current recommendation is that boys and girls ages 9 through 15 should get two-doses of HPV-9. The “catch-up” vaccine schedule is a three- dose series for females above age 15 through age 27 and males above 15 years of age to 21 years of age, if not previously vaccinated with HPV vaccine. Should ACIP expand their recommendations for use of HPV-9 vaccine in the newly approved age group, the CDC won’t be alone in the push to increase the use of the HPV vaccine by children and adults in the U.S. During the September meeting of the National Vaccine Advisory Committee (NVAC), a federal advisory committee that makes recommendations to the National Vaccine Program Office (NVPO), the HHS Assistant Secretary ADM Brett Giroir M.D. emphasized that HHS supported the NVAC’s HPV vaccine recommendations published in June 2018. Dr. Giroir stated that increasing HPV vaccination in America would be a focus for HHS in 2019. The federal government’s focus on increasing the use recommendations for the HPV vaccine may result in a renewed effort by state legislators to introduce legislation in many states to mandate HPV vaccine for school entry.
News sources from Mexico are reporting that a researcher from National Polytecnic Institute has developed a cure for the Human Papilloma Virus (HPV). Using photodynamic therapy, Dr. Eva Ramón Gallegos has been able to completely eradicate HPV in 29 patients. She has studied the effects of photodynamic therapy for 20 years, and has reportedly treated 420 patients with the therapy. As a non-invasive procedure, it is said to be an effective method to prevent malignant neoplasm, which is the second leading cause of death among Mexican women. Dr. Gallegos also explained that: "besides eradicating HPV, the main cause behind cervical cancer, photodynamic therapy is also used to eliminate premalignant lesions of cervical cancer in its first stages." The results of her work show that she was able to eradicate HPV in 100% of the patients who had the virus but had no premalignant lesions, 64.3% in women with HPV and lesions, and 57.2% in women who had lesions but don't have HPV. This is good news for HPV sufferers, but bad news for the pharmaceutical giant Merck, and their blockbuster Gardasil HPV vaccine.
French Cancer Surgeon: Statistics Show HPV Gardasil Vaccine Linked to Increased Cervical Cancer Rates After Years of Decline Due to Pap Smears
It takes a long time to affirm that a preventive action really protects. But the failure of this supposed protection can sometimes be very quickly obvious. To prove that the Titanic was truly unsinkable would have required decades of navigation on the most dangerous seas of the world. Demonstrating that it wasn’t, took only a few hours … This » Titanic » demonstration is unfortunately reproduced by the Gardasil vaccination. Evidence that vaccination increases the risk of invasive cancer can be rapid, if the vaccine changes the natural history of cancer by accelerating it. The analysis of trends in the incidence of invasive cervical cancer published in official statistics (registers) was studied in the first and most fully vaccinated countries (Australia, Great Britain, Sweden and Norway). In all countries that achieved high HPV vaccination coverage, official cancer registries show an increase in the incidence of invasive cervical cancer. These paradoxical results plea for a rapid revision of recommendations and intensive research to explain this catastrophic issue.
It was truly a red-letter day. Jennifer’s lawyers brilliantly laid bare Merck’s anemic case for Gardasil, dissecting the science in withering presentations challenging both the efficacy and safety of the Gardasil vaccine, and then chronicling the horrifying agency and corporate corruption that lead to its approval. Jennifer Robi is a 24-year-old former athlete and scholar who has been confined to a wheelchair since receiving her third Gardasil vaccines at age sixteen. She suffers continual uncontrolled neuro/muscular contractions (jerking) and postural orthostatic tachycardia syndrome (POTS) and many other symptoms of systemic autoimmune dysregulation. Jennifer’s attorney, Sol Ajalat, initially brought her case in Vaccine Injury Compensation Program and then, following a judgment in the program, elected to proceed in civil court. Since VICA (the Vaccine Injury Compensation Act) forbids recoveries for product defect or negligence, Ajalat brought Jennifer’s civil case under the theories that Merck committed fraud during its clinical trials and then failed to warn Jennifer (and, by implication, other injured girls) about the high risks and meager benefits of the vaccine. In order to support Sol Ajalat and his sons Greg, Larry, and Steve, who compose the Los Angeles firm Ajalat & Ajalat, a blue ribbon A-Team of the nation’s leading plaintiffs’ law firms have joined Jennifer’s trial team. These include the firms most feared by Pharma: Weitz & Luxenberg (countless major pieces of litigation over 30 years), Morgan & Morgan (Vioxx, Phenphen, Breast Implants, Tobacco), Baum Hedlund, (Monsanto $289 million verdict 2018 and the $54 million 2000 verdict against Bayer in Haemophiliac/AIDS case) as well as Children’s Health Defense’s own Robert F. Kennedy, Jr. and Kim Mack Rosenberg (a co-author of The HPV on Trial).